登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式(希尔记法):
C6H5NO2
化学文摘社编号:
分子量:
123.11
UNSPSC Code:
12352207
NACRES:
NA.71
PubChem Substance ID:
EC Number:
200-441-0
Beilstein/REAXYS Number:
109591
MDL number:
产品名称
烟酸, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥98%
InChI key
PVNIIMVLHYAWGP-UHFFFAOYSA-N
InChI
1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)
SMILES string
OC(=O)c1cccnc1
product line
BioReagent
assay
≥98%
form
powder
mol wt
Mw 123.11 g/mol
technique(s)
cell culture | insect: suitable
cell culture | mammalian: suitable
cell culture | plant: suitable
color
white to off-white
pH
3.4 (20 °C, 10 g/L)
mp
236-239 °C (lit.)
solubility
1 M NaOH: soluble 50 mg/mL, clear, colorless to very faintly yellow
density
1.473 g/cm3 at 25 °C
application(s)
agriculture
Quality Level
Gene Information
human ... CYP1A2(1544)
rat ... Chrnb2(54239)
正在寻找类似产品? 访问 产品对比指南
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2
存储类别
11 - Combustible Solids
wgk
WGK 1
flash_point_f
379.4 °F - closed cup
flash_point_c
193 °C - closed cup
ppe
dust mask type N95 (US), Eyeshields, Gloves
Sorin Tunaru et al.
Nature medicine, 9(3), 352-355 (2003-02-04)
Nicotinic acid (niacin), a vitamin of the B complex, has been used for almost 50 years as a lipid-lowering drug. The pharmacological effect of nicotinic acid requires doses that are much higher than those provided by a normal diet. Its
Beat Müller et al.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 20(2), 181-195 (2003-10-11)
A novel methodology for establishing a pharmacological dose-effect relationship of methyl nicotinate, hexyl nicotinate and nicotinic acid acting as peripheral vasodilators in the skin following topical application is investigated. This methodology involves the estimation of the unbound drug concentration in
John R Guyton et al.
Journal of the American College of Cardiology, 62(17), 1580-1584 (2013-08-07)
This study sought to examine the relationship between niacin treatment, lipoproteins, and cardiovascular (CV) outcomes in this secondary analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes) trial. During a
Koon K Teo et al.
Stroke, 44(10), 2688-2693 (2013-07-25)
In Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial, addition of extended-release niacin (ERN) to simvastatin in participants with established cardiovascular disease, low high-density lipoprotein cholesterol, and high triglycerides had no incremental
Paul M Lavigne et al.
Journal of the American College of Cardiology, 61(4), 440-446 (2012-12-26)
This study sought to assess the efficacy of niacin for reducing cardiovascular disease (CVD) events, as indicated by the aggregate body of clinical trial evidence including data from the recently published AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持